DCPH - Deciphera Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
36.78
-0.22 (-0.59%)
As of 10:15AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close37.00
Open37.34
Bid36.79 x 800
Ask36.92 x 1200
Day's Range35.87 - 37.80
52 Week Range18.55 - 42.99
Volume114,475
Avg. Volume610,230
Market Cap1.406B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.31
Earnings DateAug 2, 2019 - Aug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.40
Trade prices are not sourced from all markets
  • Benzinga

    The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...

  • Business Wire

    Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced registered underwritten public offering of 10,810,810 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Deciphera from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $400.0 million. The offering is expected to close on or about August 19, 2019, subject to customary closing conditions.

  • This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival
    Investor's Business Daily

    This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival

    Deciphera Pharmaceuticals continued a two-day sprint Wednesday on excitement over a stomach cancer treatment, but at least one analyst far prefers rival biotech company Blueprint Medicines.

  • Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%
    Zacks

    Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%

    Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.

  • Deciphera (DCPH) Stock at $62 a Share? Deutsche Bank Thinks It’s Possible
    TipRanks

    Deciphera (DCPH) Stock at $62 a Share? Deutsche Bank Thinks It’s Possible

    Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Deciphera Pharmaceuticals (DCPH), whose shares skyrocketed nearly 80% today.The cause of all the enthusiastic commotion? Deciphera announced positive top-line results from its pivotal Phase III study of ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumor (GIST) patients. Specifically, ripretinib has demonstrated an impressive mPFS improvement of 6.3 months which far exceeded investor expectations of ~4 months.The million-dollar question is whether Deciphera stock can keep up this strong rally. For Deutsche Bank analyst Konstantinos Aprilaki the answer is quite clear — the analyst sees this stock as a flower that keeps blossoming.Despite the appreciation in shares, Aprilaki reiterates a Buy rating on DCPH, while boosting his price target to $62 (from $42). For perspective, Deciphera’s stock closed at $35.90 today, so this implies upside of more than 70%. (To watch Aprilaki's track record, click here) Aprilaki commented, "We believe this result, coupled with the relatively clean safety profile exhibited across ripretinib clinical trials, largely de-risk the company’s planned NDA submission to the FDA in 1Q20 in the setting of advanced GIST, and thereby increase our POS in this setting from 90% to 95%. Further, we emphasize that we see positive read through to the ongoing pivotal Phase III study of ripretinib in 2L GIST (INTRIGUE), given that the active comparator in that trial, sunitinib, is associated with a mPFS of only 5.5 months; we increase our POS in this setting from 65% to 75%." "We also adjust our estimates for predicted peak duration of treatment in both 4L and 2L GIST to reflect not only the mPFS result for INVICTUS but what we see as an increased likelihood for treatment post progression given the mOS of 15.1 months reported; 8 months and 11 months, respectively. Lastly, we increase the assumed price for ripretinib in our model from $27,500/month to $30,000/month to better reflect the value proposition we see for the asset," the analyst added.Aprilaki is certainly not the first analyst with an optimistic outlook for this drug maker, as TipRanks analytics showcasing Deciphera stock as a Strong Buy. With an average price target of $44.80, analysts are predicting an upside of nearly 25%. In total, the stock has received 6 back-to-back 'buy' ratings in the last three months. (See DCPH's price targets and analyst ratings on TipRanks)

  • Why Best Buy, Deciphera Pharmaceuticals, and Genworth Financial Jumped Today
    Motley Fool

    Why Best Buy, Deciphera Pharmaceuticals, and Genworth Financial Jumped Today

    Good news on the trade front was instrumental in lifting many stocks on Tuesday.

  • This Biotech Stock Rocketed 80% In Bullish Volume On A Cancer Drug
    Investor's Business Daily

    This Biotech Stock Rocketed 80% In Bullish Volume On A Cancer Drug

    Deciphera Pharmaceuticals stock nearly doubled Tuesday after the biotech company said its stomach cancer treatment benefited patients who've exhausted at least three other options.

  • Business Wire

    Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock. J.P. Morgan, Piper Jaffray and Jefferies are acting as joint book-running managers for the offering.

  • Here's Why Deciphera Pharmaceuticals Rose as Much as 115% Today
    Motley Fool

    Here's Why Deciphera Pharmaceuticals Rose as Much as 115% Today

    Solid clinical results were just what the struggling pharma company needed.

  • TheStreet.com

    Deciphera Soars on Positive Phase III Drug Trial

    Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.

  • Reuters

    Deciphera shares skyrocket as cancer drug improves progression-free survival

    The treatment, ripretinib, was tested against placebo in 129 patients with advanced gastrointestinal stromal tumors (GIST), a rare cancer affecting the digestive tract, who had received at least 3 prior therapies. Ripretinib demonstrated a median progression-free survival rate of 6.3 months compared with a month in case of placebo, the company said, adding that the drug significantly reduced the risk of disease progression or death by 85%. According to the American Cancer Society, more than 11,000 Americans will die from stomach cancer in 2019.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 13, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Arcadia Biosciences (NASDAQ: RKDA ) shares ...

  • Deciphera stock surges on gastrointestinal cancer drug success
    American City Business Journals

    Deciphera stock surges on gastrointestinal cancer drug success

    After sixteen years of work, Waltham drugmaker Deciphera Pharmaceuticals Inc. is set to ask the FDA for permission to bring its first product to market next year.

  • MarketWatch

    Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data

    Shares of Deciphera Pharmaceuticals Inc. more than doubled toward a 14-month high in active premarket trading Tuesday, after the biopharmaceutical company said a phase 3 trial of its treatment of gastrointestinal stromal tumors (GIST) achieved its primary endpoint, paving the way for the company to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration. The stock rocketed 125% on volume of over 1.1 million shares ahead of the open, compared with the full-day average volume of about 293,000 shares. The primary endpoint of the study was improved progression free survival (PFS). A key secondary endpoint of objective response rate (ORR) was not statistically significant. The stock has lost 5.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has gained 8.0% and the S&P 500 has climbed 15.0%.

  • Reuters

    UPDATE 3-Deciphera shares skyrocket as cancer drug improves progression-free survival

    Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study. The treatment, ripretinib, was tested against placebo in 129 patients with advanced gastrointestinal stromal tumors (GIST), a rare cancer affecting the digestive tract, who had received at least 3 prior therapies. Ripretinib demonstrated a median progression-free survival rate of 6.3 months compared with a month in case of placebo, the company said, adding that the drug significantly reduced the risk of disease progression or death by 85%.

  • Business Wire

    Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors

    - Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST –

  • Business Wire

    Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

    - INVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival Versus Placebo in Patients with Fourth-line and Fourth-line Plus GIST -

  • Business Wire

    Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results

    - Top-line Data from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Fourth-line and Fourth-line Plus Gastrointestinal Stromal Tumor Patients Expected this Month -

  • Implied Volatility Surging for Deciphera (DCPH) Stock Options
    Zacks

    Implied Volatility Surging for Deciphera (DCPH) Stock Options

    Investors need to pay close attention to Deciphera (DCPH) stock based on the movements in the options market lately.

  • Business Wire

    Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors. Dr. Kelley will serve as an independent director and member of the Compensation Committee. “It is a pleasure to welcome Susan to the Board of Directors at such an exciting time for Deciphera,” said Steve Hoerter, President and Chief Executive Officer of Deciphera.

  • Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy?
    Insider Monkey

    Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH). Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders have […]

  • Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock
    Zacks

    Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock

    Deciphera Pharmaceuticals (DCPH) needs investors to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire

    Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd. (ZLAB), a China and U.S.-based innovative biopharmaceutical company, today announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFRα.